VEGFA and hepatocellular carcinoma: Recently, increasing evidence suggests that immune checkpoint inhibitors (ICIs) combined with either multi‐kinase tyrosine kinase inhibitors (TKIs) or vascular endothelial growth factor (VEGF) antibody become the trending regimens for advanced HCC.18, 19, 20, 21